Survival rates from lung cancer by patients diagnosed in Scotland is among the lowest in Europe and lung cancer is the biggest killer of all cancers. During a recent meeting the Scottish Parliament in Edinburgh by the Cross-Party Group for Cancer it was agreed that there is a strong demand to consider a formal recommendation
The Scottish Medicines Consortium has endorsed NHS funding for four therapies that new treatment options for acute myeloid leukaemia, Still’s disease, adrenal insufficiency and psoriatic arthritis. Pfizer’s Gemtuzumab ozogamicin was accepted for the treatment of acute myeloid leukaemia (AML), after being considered through the SMC’s Patient and Clinician Engagement (PACE) process. Current initial treatment for
Scottish Medicines Consortium (SMC) has published new advice accepting three new medicines for use by NHS Scotland, offering patients new treatment options for soft tissue sarcoma, acromegaly and hepatitis C. Eli Lilly’s Lartruvo was approved for the treatment of advanced soft tissue sarcoma, a rare type of cancer that affects the soft, supportive tissues within
Actelion says it is disappointed by the decision made by Scottish cost regulators to refuse NHS funding for pulmonary arterial hypertension drug Uptravi. The Scottish Medicines Consortium (SMC) issued guidance not recommending use of Uptravi (selexipag) for a sub-population of adult patients with the potentially life-threatening condition, which leads to an increase in blood pressure
Scotland is set to become the first UK nation to routinely offer HIV pre-exposure prophylaxis to eligible patients after the Scottish Medicines Consortium backed the use of Gilead’s Truvada along with four other new therapies to be funded by the NHS. In clinical trials Truvada (emtricitabine/tenofovir disoproxil) was revealed to cut the relative risk of
